SNSE Stock: Price, Forecast, Financials & AI Analysis

High

Open

VWAP

Vol

Mkt Cap

Low

Amount

EV/EBITDA(TTM)

Total Shares

EV/OCF(TTM)

P/S(TTM)

Valuation Metrics

The current forward P/E ratio for Sensei Biotherapeutics Inc (SNSE.O) is -0.61, compared to its 5-year average forward P/E of -2.58. For a more detailed relative valuation and DCF analysis to assess Sensei Biotherapeutics Inc 's fair value, click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

N/A

5Y Average PE

-2.58

Current PE

-0.61

Overvalued PE

1.22

Undervalued PE

-6.38

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

N/A

5Y Average EV/EBITDA

-0.46

Current EV/EBITDA

0.00

Overvalued EV/EBITDA

3.37

Undervalued EV/EBITDA

-4.30

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

N/A

5Y Average PS

0.00

Current PS

0.00

Overvalued PS

0.00

Undervalued PS

0.00

Financials

Annual

Quarterly

N/A

Operating Profit

N/A

Net Income after Tax

N/A

EPS - Diluted

N/A

Free Cash Flow

Trading Trends

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

Bought

Hedge Fund

Hedge Funds are Neutral. There are no significant trading trends over the last quarter.

Sold

Bought

Congress Trading

Congress are Neutral. There are no significant trading trends over the last month.

Sold

Bought

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

Bought

SNSE News & Events

Events Timeline

No data

News

2.0

12-05Benzinga

What Caused Sensei Biotherapeutics (SNSE) Stock to Surge Nearly 63% in After-Hours Trading?

2.0

12-05NASDAQ.COM

Healthcare and Biotech Stocks Surge in After-Hours Trading: Sensei, Praxis, Cooper, Vanda, Cue, ResMed

4.5

10-30Newsfilter

Sensei Biotherapeutics Launches Strategic Review Aimed at Enhancing Shareholder Value

People Also Watch

Frequently Asked Questions

What is Sensei Biotherapeutics Inc (SNSE) stock price today?

The current price of SNSE is 7.89 USD — it has decreased -7.72 % in the last trading day.

What is Sensei Biotherapeutics Inc (SNSE)'s business?

Sensei Biotherapeutics, Inc. is a clinical-stage immuno-oncology company, which is focused on the discovery and development of therapeutics for cancer patients. Through its Tumor Microenvironment Activated biologics (TMAb) platform, the Company develops conditionally active therapeutics designed to disable immunosuppressive signals or activate immunostimulatory signals selectively in the tumor microenvironment to unleash T cells against tumors. Its lead investigational candidate is SNS-101, a conditionally active antibody designed to block the V-domain Ig suppressor of T cell activation checkpoint selectively within the low pH tumor microenvironment. It is also developing SNS-102, a conditionally active monoclonal antibody targeting V-Set and Immunoglobulin Domain Containing 4 (VSIG-4); SNS-103, a conditionally active monoclonal antibody targeting ecto-nucleoside triphosphate diphosphohydrolase-1 (ENTPDase1), CD39; and SNS-201, a conditionally active VISTAxCD28 bispecific antibody.

What is the price predicton of SNSE Stock?

Wall Street analysts forecast SNSE stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for SNSE is USD with a low forecast of USD and a high forecast of USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

What is Sensei Biotherapeutics Inc (SNSE)'s revenue for the last quarter?

Sensei Biotherapeutics Inc revenue for the last quarter amounts to -4.85M USD, decreased -37.99 % YoY.

What is Sensei Biotherapeutics Inc (SNSE)'s earnings per share (EPS) for the last quarter?

Sensei Biotherapeutics Inc. EPS for the last quarter amounts to -3586000.00 USD, decreased -34.44 % YoY.

What changes have occurred in the market's expectations for Sensei Biotherapeutics Inc (SNSE)'s fundamentals?

The market is revising No Change the revenue expectations for Sensei Biotherapeutics, Inc. (SNSE) for FY2025, with the revenue forecasts being adjusted by % over the past three months. During the same period, the stock price has changed by -11.35%.

How many employees does Sensei Biotherapeutics Inc (SNSE). have?

Sensei Biotherapeutics Inc (SNSE) has 14 emplpoyees as of December 16 2025.

What is Sensei Biotherapeutics Inc (SNSE) market cap?

Today SNSE has the market capitalization of 9.95M USD.